Candel Therapeutics, Inc. (NASDAQ:CADL) Short Interest Update

Candel Therapeutics, Inc. (NASDAQ:CADL) was the recipient of a significant increase in short interest in July. As of July 15th, there was short interest totalling 1,400,000 shares, an increase of 38.6% from the June 30th total of 1,010,000 shares. Based on an average daily trading volume, of 764,700 shares, the short-interest ratio is presently 1.8 days. Approximately 7.6% of the company’s shares are sold short.

Candel Therapeutics Stock Up 2.9 %

Shares of NASDAQ CADL traded up $0.19 during trading on Friday, reaching $6.70. 170,261 shares of the stock were exchanged, compared to its average volume of 547,795. The business’s 50-day moving average price is $7.19 and its 200 day moving average price is $4.89. Candel Therapeutics has a twelve month low of $0.66 and a twelve month high of $14.30. The company has a quick ratio of 2.00, a current ratio of 2.00 and a debt-to-equity ratio of 1.66. The company has a market capitalization of $199.39 million, a price-to-earnings ratio of -5.23 and a beta of -0.95.

Candel Therapeutics (NASDAQ:CADL) last posted its earnings results on Tuesday, May 14th. The company reported ($0.28) EPS for the quarter. As a group, equities analysts forecast that Candel Therapeutics will post -0.91 EPS for the current fiscal year.

Insider Buying and Selling at Candel Therapeutics

In other Candel Therapeutics news, CEO Paul Peter Tak sold 20,293 shares of Candel Therapeutics stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $5.97, for a total transaction of $121,149.21. Following the transaction, the chief executive officer now directly owns 353,263 shares of the company’s stock, valued at $2,108,980.11. The sale was disclosed in a filing with the SEC, which is available at this link. In other news, CEO Paul Peter Tak sold 20,293 shares of the business’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $5.97, for a total transaction of $121,149.21. Following the transaction, the chief executive officer now directly owns 353,263 shares of the company’s stock, valued at $2,108,980.11. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Charles Schoch sold 8,897 shares of the business’s stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $5.97, for a total transaction of $53,115.09. Following the transaction, the insider now directly owns 72,404 shares in the company, valued at $432,251.88. The disclosure for this sale can be found here. Insiders have sold a total of 89,783 shares of company stock valued at $559,636 over the last ninety days. Corporate insiders own 41.60% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Candel Therapeutics stock. Bank of New York Mellon Corp purchased a new position in Candel Therapeutics, Inc. (NASDAQ:CADL) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 54,449 shares of the company’s stock, valued at approximately $338,000. Bank of New York Mellon Corp owned about 0.18% of Candel Therapeutics at the end of the most recent quarter. 13.93% of the stock is currently owned by hedge funds and other institutional investors.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.